

Additional File 4. Medications Presented to Modified Delphi[†]

Antihyperglycemics	Antivirals	Mineralocorticoid Receptor Antagonists
Metformin	Acyclovir	Eplerenone *
Glyburide	Famciclovir	Spironolactone
Saxagliptin	Valacyclovir	CGRP Antagonist
Sitagliptin	Oseltamivir	Atogepant *
Lipid Lowering Agents	Paxlovid *	Ubrogepant *
Bezafibrate	Truvada *	Antidepressants
Fenofibrate	Antimicrobials	Bupropion**
Rosuvastatin	Amoxicillin**	Duloxetine
Antimuscarinic Agents	Amoxicillin / Clavulanic Acid**	Venlafaxine
Solifenacin	Cephalexin**	Escitalopram
Tolterodine	Clarithromycin**	Mirtazapine
Anticonvulsants	Sulfamethoxazole / Trimethoprim	Other Drugs
Gabapentin	Ciprofloxacin	Baclofen
Pregabalin	Levofloxacin	Lithium
Topiramate	Norfloxacin *	Metoclopramide
Cenobamate*	Nitrofurantoin	Digoxin
Urate Lowering Agents	Antifungals	Methotrexate *
Allopurinol	Fluconazole	Tizanidine *
Colchicine	Analgesics / Opioids	Risperidone
Febuxostat	NSAIDs	Abrocitinib *
Anticoagulants	Codeine	Varenicline
Apixaban	Morphine	Sildenafil
Dabigatran	Tramadol	Tadalafil
Edoxaban	H2RA Antagonists	Sotalol
Rivaroxaban	Ranitidine	Amantadine
Dalteparin	Famotidine	Memantine
Tinzaparin	Non-Steroidal Mineralocorticoid Receptor Antagonist	Proton Pump Inhibitors (PPI) *
Enoxaparin	Finerenone *	

Paxlovid = Nirmatrelvir / Ritonavir; Truvada = Emtricitabine / Tenofovir Disoproxil Fumarate

[†]includes 64 medications identified from the scoping review

* Twelve unique medications identified only from the scoping review. Note: PPIs broader drug class was not included in modified Delphi as will be incorporated into translation efforts

** Five additional medications added from participants in round 1 for round 2